Formal Grant of US Patent
Futura Medical plc has been granted a US continuation patent, No. 12,576,152, by the US Patent Office, providing protection for Eroxon® and the women's product WSD4000 until 2040. This patent grant is expected to trigger a US$2.5 million milestone payment from Haleon under their existing licence agreement, which is a significant positive development for the company.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Further to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to announce that the US Patent Office has formally granted its US continuation patent No. 12,576,152 which will provide additional protection for Eroxon® (including formulation derivatives such as the Eroxon® Intense formulation) and women's product WSD4000 (currently in development) until 2040 in the US.
Under the terms of its existing licence agreement with Haleon, the granting of this patent is expected to trigger a US patent milestone payment of US$2.5 million.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.